type here...

CATEGORIES

Rare and Orphan Diseases

LATEST

12Page 2 of 2

TRENDING

EDITORS CHOICE

Biotech Without Borders: Reclaiming the Wonder of Science in a Distracted Age

Gil Bashe, Medika Life Editor -
I was in the media bullpen with the team when the future arrived. The launch of Roferon-A, alpha interferon marked a watershed moment in medicine:...

Real-World Evidence Unlocks Consumer Voice to Improve Care

Gil Bashe, Medika Life Editor -
Patient Experience is the Key to Improving Drug Development and Health Care, but Are We Listening?

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

Gil Bashe, Medika Life Editor -
Craig Martin is a strategic chameleon in health innovation. He is equally at home in boardrooms, nonprofit leadership, consulting and advisory roles, all with...

Treating Rare Diseases: The Challenge of Access

Ravi Santani MD -
Although rare by definition, the collective impact of rare diseases is anything but insignificant. In the Asia-Pacific (APAC) region – home to over half of...

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories